Home › Compare › CEBTF vs ABBV
CEBTF yields 18181.82% · ABBV yields 3.06%● Live data
📍 CEBTF pulled ahead of the other in Year 1
Combined, CEBTF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CEBTF + ABBV for your $10,000?
Citychamp Watch & Jewellery Group Limited, an investment holding company, manufactures, sells, and distributes watches and timepieces in Hong Kong, the People's Republic of China, Switzerland, the United Kingdom, Liechtenstein, and internationally. The company operates through Manufacturing and Distribution of Watches and Timepieces, Property Investments, and Banking and Financial Businesses segments. It offers watches and timepieces under the Rossini, Corum, Eterna, Dreyfuss & Co, J&T Windmills, Ernest Borel, and Rotary brands. The company is also involved in the property investment activities; distribution of glasses; and issuance of bonds. In addition, it operates a bank in Liechtenstein that offer financial services, including accepting client deposits and granting loans; and portfolio management, investment advice, transaction banking, and investment fund services for entrepreneurial families and individuals. Further, the company provides investment counselling services; acts as technical administrator of fund units; dealing and advising in securities; and watch maintenance and repairment, and technical advisory services, as well as acts as an alternative investment fund manager. The company was formerly known as China Haidian Holdings Limited and changed its name to Citychamp Watch & Jewellery Group Limited in May 2014. Citychamp Watch & Jewellery Group Limited is based in Kowloon, Hong Kong.
Full CEBTF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.